{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:38:03Z","timestamp":1788395883631,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Parkinson Society of Canada"},{"name":"Canada Research Chair in Molecular Neuropharmacology"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.nbd.2011.10.011","type":"journal-article","created":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T19:32:44Z","timestamp":1319052764000},"page":"645-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model"],"prefix":"10.1016","volume":"45","author":[{"given":"Laure","family":"Chagniel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Robitaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Lebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2011.10.011_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2011.10.011_bb0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.parkreldis.2007.09.005","article-title":"Activation of the calpain\/cdk5\/p25 pathway in the girus cinguli in Parkinson's disease","volume":"14","author":"Alvira","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2011.10.011_bb0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.10.011_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/WNF.0B013E3181761466","article-title":"Calcium homeostasis is dysregulated in parkinsonian patients with l-DOPA-induced dyskinesias","volume":"32","author":"Blandini","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson's disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/mds.870130603","article-title":"Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease","volume":"13","author":"Brotchie","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2011.10.011_bb0040","first-page":"454","article-title":"Recent advances in the treatment of l-DOPA-induced dyskinesia","volume":"5","author":"Brown","year":"2002","journal-title":"IDrugs"},{"key":"10.1016\/j.nbd.2011.10.011_bb0045","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1046\/j.1471-4159.2000.741229.x","article-title":"l-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion","volume":"74","author":"Camp","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.physbeh.2005.01.019","article-title":"Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate","volume":"84","author":"Castaneda","year":"2005","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.nbd.2011.10.011_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00726-001-0116-4","article-title":"Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease","volume":"23","author":"Cenci","year":"2002","journal-title":"Amino Acids"},{"key":"10.1016\/j.nbd.2011.10.011_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in l-DOPA-induced dyskinesia","volume":"183","author":"Cenci","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0070","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0075","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0080","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1523\/JNEUROSCI.23-10-04081.2003","article-title":"Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease","volume":"23","author":"Crocker","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0090","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/35096019","article-title":"A decade of CDK5","volume":"2","author":"Dhavan","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1460-9568.1996.tb01220.x","article-title":"Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum","volume":"8","author":"Doucet","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0365","first-page":"419","article-title":"A new look at levodopa based on the ELLDOPA study","author":"Fahn","year":"2006","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.nbd.2011.10.011_bb0105","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1089\/hum.1998.9.17-2527","article-title":"Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic l-amino acid decarboxylase genes using two separate adeno-associated virus vectors","volume":"9","author":"Fan","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2011.10.011_bb0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbr.2004.05.024","article-title":"An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate","volume":"156","author":"Fleming","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for Parkinson disease","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0120","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1523\/JNEUROSCI.22-12-05042.2002","article-title":"D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1\/2\/MAP kinase","volume":"22","author":"Gerfen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0125","doi-asserted-by":"crossref","first-page":"14695","DOI":"10.1074\/jbc.M609713200","article-title":"The in vivo phosphorylation sites of rat brain dynamin I","volume":"282","author":"Graham","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.neuroscience.2008.10.023","article-title":"Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats","volume":"158","author":"Grant","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.10.011_bb0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/00207451003797694","article-title":"Effect of cdk5 antagonist on l-dopa-induced dyskinesias in a rat model of Parkinson's disease","volume":"120","author":"Guan","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0140","first-page":"1311","article-title":"CYC-202 Cyclacel","volume":"5","author":"Guzi","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.nbd.2011.10.011_bb0145","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/jcbfm.2008.75","article-title":"Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma","volume":"28","author":"Hilton","year":"2008","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nbd.2011.10.011_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2004.07.005","article-title":"Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia","volume":"17","author":"Konradi","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.10.011_bb0165","doi-asserted-by":"crossref","first-page":"17166","DOI":"10.1074\/jbc.M907757199","article-title":"Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25","volume":"275","author":"Kusakawa","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nbd.2009.12.027","article-title":"Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat","volume":"38","author":"Lebel","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"Pt 7","key":"10.1016\/j.nbd.2011.10.011_bb0175","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","article-title":"Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"123","author":"Lee","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2011.10.011_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/35012636","article-title":"Neurotoxicity induces cleavage of p35 to p25 by calpain","volume":"405","author":"Lee","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2011.10.011_bb0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","article-title":"The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration","volume":"177","author":"Lindgren","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0370","doi-asserted-by":"crossref","first-page":"re1","DOI":"10.1126\/stke.114re1","article-title":"Calpain in the CNS: from synaptic function to neurotoxicity","volume":"1","author":"Liu","year":"2008","journal-title":"Sci. Signal."},{"key":"10.1016\/j.nbd.2011.10.011_bb0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.expneurol.2005.11.002","article-title":"Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?","volume":"197","author":"Marin","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/01.STR.29.1.152","article-title":"Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats","volume":"29","author":"Markgraf","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.nbd.2011.10.011_bb0210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0215","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0306-4522(96)00100-5","article-title":"Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?","volume":"73","author":"Mouatt-Prigent","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.10.011_bb0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","article-title":"Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions","volume":"43","author":"Murer","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004010050687","article-title":"p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease","volume":"94","author":"Nakamura","year":"1997","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pavon","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.nbd.2011.10.011_bb0245","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.nbd.2011.10.011_bb0250","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbr.2006.03.021","article-title":"Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment","volume":"171","author":"Pinna","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0260","first-page":"229","article-title":"Levodopa in the treatment of Parkinson's disease: an old drug still going strong","volume":"5","author":"Poewe","year":"2010","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.nbd.2011.10.011_bb0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2011.10.011_bb0270","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0275","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"Sauer","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2011.10.011_bb0280","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2011.10.011_bb0285","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biopsych.2008.09.008","article-title":"Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of l-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"65","author":"Schuster","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.nbd.2011.10.011_bb0290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0295","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.gt.3300776","article-title":"Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism","volume":"5","author":"Segovia","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.nbd.2011.10.011_bb0300","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1089\/10430340050083243","article-title":"Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-l-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease","volume":"11","author":"Shen","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2011.10.011_bb0305","first-page":"277","article-title":"Cdk5 on the brain","volume":"12","author":"Smith","year":"2001","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.nbd.2011.10.011_bb0310","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1073\/pnas.2232515100","article-title":"Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease","volume":"100","author":"Smith","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2011.10.011_bb0315","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1523\/JNEUROSCI.2875-05.2006","article-title":"Calpain-regulated p35\/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2","volume":"26","author":"Smith","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2011.10.011_bb0320","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pbb.2005.06.013","article-title":"Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat","volume":"81","author":"Taylor","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.nbd.2011.10.011_bb0325","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1089\/neu.2010.1474","article-title":"A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model","volume":"27","author":"Thompson","year":"2010","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.nbd.2011.10.011_bb0330","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1073\/pnas.1003432107","article-title":"Presynaptic dopaminergic compartment determines the susceptibility to l-DOPA-induced dyskinesia in rats","volume":"107","author":"Ulusoy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2011.10.011_bb0335","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2174\/138955707782110114","article-title":"Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus","volume":"7","author":"Wei","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.nbd.2011.10.011_bb0340","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.nbd.2011.10.011_bb0345","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2011.10.011_bb0350","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s11064-007-9347-4","article-title":"Sustained calpain inhibition improves locomotor function and tissue sparing following contusive spinal cord injury","volume":"32","author":"Yu","year":"2007","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.nbd.2011.10.011_bb0355","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0002-9440(10)63347-0","article-title":"Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice","volume":"165","author":"Zhang","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2011.10.011_bb0360","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/104303404322959498","article-title":"Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter","volume":"15","author":"Zhang","year":"2004","journal-title":"Hum. Gene Ther."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996111003433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996111003433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T14:43:42Z","timestamp":1714661022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996111003433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0969996111003433"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2011.10.011","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2011.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}